Table 2 MMP-9 gene expression and... | American Society of Hematology

Table 2

MMP-9 gene expression and percent cytogenetically marked cells in patients with MDS

Patient no.	Chromosomal abnormality	Percent marked CD14⁺ cells*	Percent marked marrow†	Percent marrow cellularity	Induced expression of MMP-9
3	del 20q	NA	55	70	5.18
4	t(2:11), del 5p, del X	NA	100	90	6.84
5	del 20q	64	75	100	7.23
6	inv 16	NA	45	98	9.25
7	t(1:7), del 7p	NA	65	90	11.66
8	t(1:7), del 7	NA	17	20	14.10
10	tri 15	7	18	40	15.61
12	del 12	NA	85	95	3.15
13	tri 8	NA	95	98	7.02
17	del 20q, t(13:14)	NA	85	60	11.41
25	del 20q	84	100	65	6.45

Patient no.	Chromosomal abnormality	Percent marked CD14⁺ cells*	Percent marked marrow†	Percent marrow cellularity	Induced expression of MMP-9
3	del 20q	NA	55	70	5.18
4	t(2:11), del 5p, del X	NA	100	90	6.84
5	del 20q	64	75	100	7.23
6	inv 16	NA	45	98	9.25
7	t(1:7), del 7p	NA	65	90	11.66
8	t(1:7), del 7	NA	17	20	14.10
10	tri 15	7	18	40	15.61
12	del 12	NA	85	95	3.15
13	tri 8	NA	95	98	7.02
17	del 20q, t(13:14)	NA	85	60	11.41
25	del 20q	84	100	65	6.45

Del indicates deletion; NA not available; inv, inversion; tri 15, trisomy 15.

Determined by FISH analysis of blood-derived CD14⁺ cells by FHCRC Cytogenetics Laboratory.

Determined by karyotype analysis in cultured marrow cells conducted by FHCRC Cytogenetics Laboratory.